Journey Medical (DERM) Common Equity (2020 - 2026)

Journey Medical has reported Common Equity for 7 years, with the latest figure at $30.8 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 43.13% year-over-year to $30.8 million; the trailing twelve-month figure through Mar 2026 stood at $30.8 million (up 43.13% YoY), and the FY2025 full-year result was $31.9 million, up 58.71% from the prior year.
• Common Equity for Q1 2026 stood at $30.8 million, down from $31.9 million in the prior quarter.
• The five-year high for Common Equity was $41.4 million in Q1 2022, with the low at $5000.0 in Q2 2023.
• Historically, Common Equity has averaged $20.5 million across 5 years, with a median of $20.1 million in 2024.
• Annual changes were most pronounced in 2023 — Common Equity slumped 99.99% — and 2024, when it soared 225800.0%.
• Journey Medical's Common Equity stood at $17.0 million in 2022, then rose by 19.83% to $20.3 million in 2023, then fell by 1.38% to $20.1 million in 2024, then soared by 58.71% to $31.9 million in 2025, then fell by 3.21% to $30.8 million in 2026.
• The last three Common Equity figures came in at $30.8 million (Q1 2026), $31.9 million (Q4 2025), and $25.9 million (Q3 2025), per Business Quant data.